The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients
- PMID: 2008157
- DOI: 10.1016/0024-3205(91)90438-h
The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients
Abstract
The short-term effects of fluphenazine on plasma HVA concentrations were compared with the effects of fluphenazine and concurrent administration of debrisoquin, a monoamine oxidase inhibitor which does not cross the blood brain barrier and is used to enhance the CNS contribution to circulating plasma HVA concentrations. Fluphenazine significantly increased plasma HVA with or without debrisoquin 24 hours following the initiation of treatment. Domperidone, a butyrophenone dopamine antagonist which acts only in the peripheral nervous system, failed to alter plasma HVA concentrations. These data suggest that the acute effects of neuroleptic drugs on plasma HVA concentrations are dependent upon interaction with CNS dopaminergic systems and provide additional support for the use of plasma HVA as a reflection of CNS dopamine system activity in clinical studies.
Similar articles
-
Brain contribution to the haloperidol-induced increase in plasma homovanillic acid.Eur J Pharmacol. 1981 May 8;71(2-3):321-6. doi: 10.1016/0014-2999(81)90034-0. Eur J Pharmacol. 1981. PMID: 7250191
-
Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients.Ann N Y Acad Sci. 1988;537:339-46. doi: 10.1111/j.1749-6632.1988.tb42118.x. Ann N Y Acad Sci. 1988. PMID: 2904783 Review.
-
Effects of debrisoquin on CSF and plasma HVA concentrations in man.Life Sci. 1985 Jun 3;36(22):2163-70. doi: 10.1016/0024-3205(85)90313-3. Life Sci. 1985. PMID: 3999921 Clinical Trial.
-
Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.Arch Gen Psychiatry. 1986 Jul;43(7):669-76. doi: 10.1001/archpsyc.1986.01800070059008. Arch Gen Psychiatry. 1986. PMID: 3718170 Clinical Trial.
-
Perspectives on a time-dependent model of neuroleptic action.Schizophr Bull. 1988;14(2):255-68. doi: 10.1093/schbul/14.2.255. Schizophr Bull. 1988. PMID: 2904694 Review.
Cited by
-
GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients.Neurochem Res. 2010 Feb;35(2):247-53. doi: 10.1007/s11064-009-0048-z. Epub 2009 Aug 22. Neurochem Res. 2010. PMID: 19701707
-
Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia.Neurochem Res. 2013 Feb;38(2):433-42. doi: 10.1007/s11064-012-0937-4. Epub 2012 Dec 2. Neurochem Res. 2013. PMID: 23212700 Clinical Trial.
-
Disturbance of neurotransmitter metabolites in peripheral blood of schizophrenia patients treated with olanzapine: a preliminary targeted metabolomic study.BMC Psychiatry. 2025 Feb 18;25(1):142. doi: 10.1186/s12888-025-06584-y. BMC Psychiatry. 2025. PMID: 39966737 Free PMC article.
-
Variability of plasma homovanillic acid over 13 months in patients with schizophrenia; relationship with the clinical response and the Wisconsin card sort test.Neurochem Res. 2011 Aug;36(8):1336-43. doi: 10.1007/s11064-011-0448-8. Epub 2011 Apr 8. Neurochem Res. 2011. PMID: 21475956
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical